IP Library Granted Patent US 12,329,149
Granted Patent B2
US 12,329,149 · App. 16/593,314 · Granted Jun 17, 2025

Apparatus and methods for irradiating organ perfusates

Inventors: Vanderlei Salvador Bagnato (São Barlos, BR); Marcelo Cypel (Toronto, CA); Shafique Keshavjee (Toronto, CA); Thomas Kenneth Waddell (Toronto, CA); Marcos Theophilo Galasso (Toronto, CA)
Assignees: University Health Network; Universidade de Sao Paulo
A01N1/143A01N1/168A61L2/0047A61L2/0052A61L2/10A61L2202/11A61L2202/14A61L2202/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,329,149
App. No.
16/593,314
Granted
Jun 17, 2025
Kind
B2
Abstract

Disclosed are apparatuses and methods for irradiating a perfusate. The apparatus includes a tank which defines a first chamber. A separator is located inside the first chamber. The separator defines a second chamber. The first chamber and the second chamber are concentric and have substantially annular cross sections, each having at least one diameter and a substantially common longitudinal axis. A perfusate is introduced into the first chamber by an inlet. A UV radiation-emitting device is disposed inside the second chamber for providing irradiation to the perfusate. Irradiated perfusate is removed from the tank by an outlet. Other apparatuses and systems are described and methods for inactivating micro organisms by performing EVP and irradiating the perfusate.

Claims (41)

1. A method for inactivating microorganisms, including viruses and bacteria, in a donor organ, the method comprising:

a. performing ex vivo perfusion (EVP) on the donor organ using a perfusion solution to produce a perfusate;

b. exchanging the perfusate or a portion thereof with additional perfusion solution; and

c. performing EVP on the donor organ for a subsequent period and, during the subsequent period, irradiating the perfusate with light therapy by flowing the perfusate through an irradiator at 0.1 to 3 liters per minute.

2. The method of claim 1 , wherein the perfusate is irradiated with UVC light irradiation.

3. The method of claim 1 wherein the perfusion solution comprises a photoactivator such as methylene blue and/or wherein the method comprises introducing such photoactivator into the perfusate solution prior to or during irradiating the perfusate with visible light, or optionally red light.

4. The method claim 1 , wherein the microorganism is a virus optionally one or more of Hepatitis C virus (HCV), HIV, Hepatitis B virus, Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus; or is a bacteria optionally one or more of staphylococcal bacteria, such as Staphylococcus aureus; Stenotrophomonas maltophilia ; and pseudomonad bacteria, such as Psuedomonas aeruginosa.

5. The method of claim 1 , wherein the EVP is performed for at least or about 2 hours.

6. The method of claim 1 , wherein the perfusate is irradiated for at least 1 hour.

7. The method of claim 1 , wherein the donor organ is known to be infected and the method is for decontaminating the donor organ prior transplantation.

8. The method of claim 1 , wherein the donor organ is a lung, kidney, heart or liver and/or the perfusion solution is for perfusing heart, kidney or liver.

9. The method of claim 1 , wherein the perfusate or portion thereof is changed at most about every hour.

10. A method for rescuing donor organs comprising:

a. perfusing a donor organ obtained from an individual suffering from an infection with a perfusion solution in an ex-vivo system for a first period of time, where said infection would have disqualified said organ for use in transplantation, and where said period of time is determined on the basis that the individual was not infected to produce a perfusate;

b. exchanging the perfusate or a portion thereof with additional perfusion solution;

c. irradiating said perfusate for a second period of time, applied concurrently with the perfusion of said organ, wherein said second period of time being no greater than 9 hours; and

d. transplanting said organ into a recipient other than the individual suffering from the infection.

11. The method of claim 10 , wherein the perfusate is irradiated for at least 2 hours.

12. A method of transplanting an organ, the method comprising perfusing an infected organ from a donor with a perfusion solution by ex vivo perfusion (EVP) to provide a perfusate;

exchanging the perfusate or a portion thereof with additional perfusion solution;

irradiating the perfusate with a light therapy selected from UVC or PDT for at least 2 hours by flowing the perfusate through an irradiator at 0.1 to 3 liters per minute;

transplanting the perfused and light therapy treated organ into a subject other than the donor.

13. The method of claim 1 , wherein the method comprises using an irradiation apparatus to irradiate the perfusate, the irradiation apparatus comprising:

a lower unit;

an upper unit pivotally mounted on the lower unit such that the upper unit is moveable with respect to the lower unit to open and close the apparatus;

at least one radiation source mounted on one of the lower and upper units;

wherein the upper and lower units define a chamber for receiving a receptacle, and wherein each of the side panels of the lower unit defines a groove adapted to support a body portion of the receptacle 1 .

14. The method of claim 13 wherein the at least one radiation source comprises an ultraviolet lamp, optionally wherein the ultraviolet lamp comprises one of: ultraviolet-A lamp, ultraviolet-B and ultraviolet-C.

15. The method of claim 1 , wherein the perfusate is irradiated by an irradiation system comprising:

an irradiation apparatus and a receptacle;

the irradiation apparatus comprising a lower unit and an upper unit pivotally mounted on the lower unit such that the upper unit is moveable with respect to the lower unit to open and close the apparatus;

at least one radiation source mounted on one of the lower and upper units;

wherein the upper and lower units define a chamber for receiving a receptacle and a side panel of the lower unit defines a groove adapted to support a body portion of the receptacle;

the receptacle comprising an inlet by which a solution can be introduced into the receptacle; and an outlet by the solution can be removed therefrom, wherein gripping means are machined at ends of the inlet and outlet for providing a snuggly fit when the receptacle is connected to external tubes.

16. The method of claim 15 wherein the at least one radiation source comprises an ultraviolet lamp, optionally wherein the ultraviolet lamp comprises one of: ultraviolet-A lamp, ultraviolet-B and ultraviolet-C.

17. The method of claim 15 further comprising safety sensors for detecting when the upper unit is in close contact with the lower unit, such that the sensors detect when the apparatus is open and/or closed and for preventing the apparatus from being inadvertently activated while the apparatus is open.

18. The method of claim 2 , wherein the irradiator comprises at least one UVC lamp that produces 13 mW/cm{circumflex over ( )}2 to 49 mW/cm{circumflex over ( )}2 of UVC light.

19. The method of claim 12 , wherein the irradiator comprises at least one UVC lamp that produces 13 mW/cm{circumflex over ( )}2 to 49 mW/cm{circumflex over ( )}2 of UVC light.

20. The method of claim 10 , wherein irradiating said perfusate for a second period of time comprises flowing the perfusate through an irradiator at 0.1 to 3 liters per minute.

21. The method of claim 1 , wherein a temperature inside the irradiator while irradiating the perfusate is 30 degrees Celsius to 44 degrees Celsius.

22. The method of claim 1 , wherein the perfusate is irradiated with light therapy at normothermic temperature for at least two hours.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2020
From: CYPEL, MARCELO; GALASSO, MARCOS T; KESHAVJEE, SHAFIQUE; WADDELL, THOMAS K
To: UNIVERSITY HEALTH NETWORK
Reel/Frame 053146/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2020
From: CYPEL, MARCELO; GALASSO, MARCOS T; KESHAVJEE, SHAFIQUE; WADDELL, THOMAS K
To: UNIVERSITY HEALTH NETWORK
Reel/Frame 053146/0844 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2020
From: CYPEL, MARCELO; GALASSO, MARCOS T; KESHAVJEE, SHAFIQUE; WADDELL, THOMAS K
To: UNIVERSITY HEALTH NETWORK
Reel/Frame 053110/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2020
From: BAGNATO, VANDERLEI SALVADOR
To: UNIVERSIDADE DE SAO PAULO
Reel/Frame 052286/0234 →
Continuity (3)
Continuation In Part 16500657
Provisional Application 62481523 · Apr 4, 2017
Related Publication 20200138015A1 · May 7, 2020
References Cited (52)
US 5128043A · Wildermuth · 1992 [cited by examiner]
US 6447720B1 · Horton, III et al. · 2002 [cited by applicant]
US 6899355B2 · Klein et al. · 2005 [cited by applicant]
US 6972415B2 · Schaible et al. · 2005 [cited by applicant]
US 7425272B2 · Butters et al. · 2008 [cited by applicant]
US 7687045B2 · Lu · 2010 [cited by applicant]
US 7888656B2 · Freedgood · 2011 [cited by applicant]
US 7993580B2 · Anderle · 2011 [cited by applicant]
US 20030049809A1 · Kaiser et al. · 2003 [cited by applicant]
US 20070202485A1 · Nees · 2007 [cited by examiner]
US 20100056643A1 · Bachynsky · 2010 [cited by examiner]
US 20140334974A1 · Rasooly · 2014 [cited by applicant]
US 20180070583A1 · Paul et al. · 2018 [cited by applicant]
US 20190033419A1 · Golay · 2019 [cited by examiner]
US 20200253195A1 · Bagnato et al. · 2020 [cited by applicant]
CA 2373673C · 2011 [cited by examiner]
CN 1320014A · 2001 [cited by applicant]
CN 1565654A · 2005 [cited by applicant]
CN 100369633C · 2008 [cited by applicant]
CN 101360522A · 2009 [cited by applicant]
CN 102241427A · 2011 [cited by applicant]
CN 102361823A · 2012 [cited by applicant]
CN 204910182U · 2015 [cited by applicant]
WO 1988005261A1 · 1988 [cited by applicant]
WO WO8805261A · 1988 [cited by examiner]
WO WO8805261A1 · 1988 [cited by examiner]
WO WO2016090498A1 · 2016 [cited by examiner]
WO WO2016207335A1 · 2016 [cited by examiner]
Steinmann et al., (“Two Pathogen Reduction Technologies-Methylene Blue Plus Light and Shortwave Ultraviolet Light-Effectively Inactivate Hepatitis C Virus in Blood Products.” Transfusion, 2013, vol. 53, No. 5, pp. 1010-… [cited by examiner]
Extended European Search Report dated Mar. 15, 2021, directed to European Application No. 18780312.7; 11 pages. [cited by applicant]
International Search Report and Written Opinion dated Jun. 12, 2018 directed to International Application No. PCT/CA2018/050400; 14 pages. [cited by applicant]
Notification of the First Office Action dated Oct. 14, 2020, directed to CN Application No. 201880030158; 18 pages. [cited by applicant]
Galasso, M. et al., “Inactivating Hepatitis C Virus in Donor Lungs Using Light Therapies During Normothermic Ex Vivo Lung Perfusion.” Nature Communications, 2019, 12 pages. [cited by applicant]
Khan, B. et al., “Successful Lung Transplantation From Hepatitis C Positive Donor to Seronegative Recipient.” American Journal of Transplantation, 2017, vol. 17, pp. 1129-1131. [cited by applicant]
Inci, I. et al., “Ex Vivo Reconditioning of Marginal Donor Lungs Injured by Acid Aspiration.” The Journal of Heart and Lung Transplantation, 2008, vol. 27, No. 11, pp. 1229-1236. [cited by applicant]
Nakajima, D. et al., “Lung Lavage and Surfactant Replacement During Ex Vivo Lung Perfusion for Treatment of Gastric Acid Aspiration-Induced Donor Lung Injury.” The Journal of Heart and Lung Transplantation, 2017, vol. 3… [cited by applicant]
Machuca, T.N. et al., “Lung Transplantation With Donation After Circulatory Determination of Death Donors and the Impact of Ex Vivo Lung Perfusion.” DCDD Lung Transplantation and EVLP. American Journal of Transplantatio… [cited by applicant]
Machuca, T.N. et al., “Injury-Specific Ex Vivo Treatment of the Donor Lung: Pulmonary Thrombolysis Followed by Successful Lung Transplantation.” American Journal of Respiratory and Critical Care Medicine, 2013; vol. 188… [cited by applicant]
Mohr, H. et al., “A Novel Approach to Pathogen Reduction in Platelet Concentrates Using Short-Wave Ultraviolet Light.” Transfusion, 2009, vol. 49, No. 12, pp. 2612-2624. [cited by applicant]
Steinmann, E. et al., “Two Pathogen Reduction Technologies-Methylene Blue Plus Light and Shortwave Ultraviolet Light-Effectively Inactivate Hepatitis C Virus in Blood Products.” Transfusion, 2013, vol. 53, No. 5, pp. 10… [cited by applicant]
Floyd, R. A. et al., “Methylene Blue Photoinactivation of RNA Viruses.” Antiviral Research, 2004, vol. 61, No. 3, pp. 141-151. [cited by applicant]
Müller-Breitkreutz, K, et al., “Hepatitis C and Human Immunodeficiency Virus RNA Degradation By Methylene Blue/Light Treatment of Human Plasma.” Journal of Medical Virology, 1998, vol. 56, No. 3, pp. 239-245. [cited by applicant]
Bachmann, B. et al., “Target Structures for HIV-1 Inactivation by Methylene Blue and Light.” Journal of Medical Virology, 1995, vol. 47, No. 2, pp. 172-178. [cited by applicant]
Smith, D. B. et al., “Variation of the Hepatitis C Virus 5′ Non-Coding Region: Implications for Secondary Structure, Virus Detection and Typing.” Journal of General Virology, 1995, vol. 76, No. 7, pp. 1749-1761. [cited by applicant]
Wakita T., “Isolation of JFH-1 Strain and Development of an HCV Infection System.” Hepatitis C: Methods and Protocols, Second Edition, vol. 510, Humana Press, 2009, pp. 305-327. [cited by applicant]
Examination Report No. 1 dated Jun. 30, 2022, directed to AU Application No. 2018247584; 6 pages. [cited by applicant]
European Patent Application No. EP18780312, Supplementary Partial European Search Report, dated Dec. 2, 2020, 4 pages. [cited by applicant]
Bagnato et al., U.S. Office Action mailed Feb. 24, 2023, directed to U.S. Appl. No. 16/500,657; 11 pages. [cited by applicant]
Bagnato et al., U.S. Office Action mailed Aug. 18, 2023, directed to U.S. Appl. No. 16/500,657; 12 pages. [cited by applicant]
Bagnato et al., U.S. Office Action dated Mar. 7, 2024, directed to U.S. Appl. No. 16/500,657; 12 pages. [cited by applicant]
Office Action dated Aug. 14, 2024, directed to EP Application No. 18780312.7; 7 pages. [cited by applicant]
Office Action dated Aug. 2, 2024, directed to CA Application No. 3,095,787; 4 pages. [cited by applicant]